BeOne Medicines (FRA:49BA) YoY EBITDA Growth: 166.91% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:49BA BeOne Medicines Ltd FRA:49BA
82 GF Score
Price €304.00
GF Value €320.53
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is BeOne Medicines YoY EBITDA Growth?

BeOne Medicines FRA:49BA +4.11% 82 YoY EBITDA Growth is 166.91% as of Jun. 2026. GuruFocus rates FRA:49BA with a GF Score™ of 82/100 and a GF Value™ of €320.53 (Fairly Valued). The stock has 5 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. BeOne Medicines's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 166.91%.

BeOne Medicines's EBITDA per Share for the three months ended in Jun. 2026 was €2.94.

BeOne Medicines YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for BeOne Medicines's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines YoY EBITDA Growth Chart

BeOne Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.06 -18.79 59.14 52.23 250.80

BeOne Medicines Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 251.10 457.55 641.53 393.07 166.91
FRA:49BA
82GF Score
BeOne Medicines Ltd FRA:49BA
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BeOne Medicines YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

BeOne Medicines's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(4.643--3.079)/ | -3.079 |
=250.80 %

BeOne Medicines's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(2.944-1.103)/ | 1.103 |
=166.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 166.91% mean?
BeOne Medicines (FRA:49BA) has a YoY EBITDA Growth of 166.91% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for BeOne Medicines and its competitors.
Is BeOne Medicines' YoY EBITDA Growth too high?
BeOne Medicines' current YoY EBITDA Growth is 166.91%. Overall, BeOne Medicines has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' YoY EBITDA Growth compare to RVMD and MRNA?
BeOne Medicines' YoY EBITDA Growth of 166.91% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for BeOne Medicines and its competitors. BeOne Medicines's current YoY EBITDA Growth is 166.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (FRA:49BA) is currently considered Fairly Valued. The stock's GF Value™ is €320.53, compared to a current price of €304.00 — trading 5.2% below its estimated fair value. The current YoY EBITDA Growth is 166.91%. BeOne Medicines' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For BeOne Medicines (FRA:49BA), the current YoY EBITDA Growth is 166.91% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (FRA:49BA) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of €304.00 is trading 5.2% below its estimated GF Value™ of €320.53. GuruFocus considers BeOne Medicines to be Fairly Valued.

Key valuation signals for FRA:49BA:

  • YoY EBITDA Growth: 166.91%
  • GF Value™: €320.53 vs. price of €304.00 (5.2% below fair value)
  • GF Score™: 82/100 with 5 warning signs

No single metric tells the full story. See the FRA:49BA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
82GF Score

Get the complete analysis for FRA:49BA

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€304.00
Price
€320.53
GF Value